Warfarin pharmacogenetics: Development of a dosing algorithm for Omani patients

Journal of Human Genetics

Volumn 57, Issue 10, 2012, Pages 665-669

  Pathare, Anil ^a   Al Khabori, Murtadha ^a   Alkindi, Salam ^a,b   Al Zadjali, Shoaib ^a   Misquith, Rhea ^a   Khan, Hammad ^a   Lapoumeroulie, Claudine ^c   Paldi, Andras ^d   Krishnamoorthy, Rajagopal ^c  

^a SULTAN QABOOS UNIVERSITY HOSPITAL   (Oman)

^b SULTAN QABOOS UNIVERSITY   (Oman)

^c HÔPITAL ROBERT DEBRÉ   (France)

^d GÉNÉTHON   (France)

Author keywords

admixture; CYP2C9; CYP4F2; resistance; sensitive; VKORC1; Warfarin

Indexed keywords

CYTOCHROME P450; CYTOCHROME P450 2C9; CYTOCHROME P450 4F2; PROTEIN; UNCLASSIFIED DRUG; VKORC1 PROTEIN; WARFARIN;

ADULT; AGE; ALGORITHM; ANTIPHOSPHOLIPID SYNDROME; ARTERY THROMBOSIS; ARTICLE; ASIAN; BODY WEIGHT; CASE REPORT; CAUCASIAN; COHORT ANALYSIS; CONGESTIVE CARDIOMYOPATHY; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DEMOGRAPHY; DOSE CALCULATION; ETHNIC DIFFERENCE; FEMALE; GENDER; GENE LINKAGE DISEQUILIBRIUM; GENE LOCUS; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HEART ATRIUM FIBRILLATION; HOMOZYGOTE; HUMAN; INTERNATIONAL NORMALIZED RATIO; LUNG EMBOLISM; MAINTENANCE DRUG DOSE; MAJOR CLINICAL STUDY; MALE; NEGRO; NUCLEOTIDE SEQUENCE; PARAPLEGIA; PHARMACOGENETICS; PREDICTIVE VALUE; VEIN THROMBOSIS;

ADULT; AGED; ALGORITHMS; ARYL HYDROCARBON HYDROXYLASES; ATRIAL FIBRILLATION; CYTOCHROME P-450 ENZYME SYSTEM; DRUG DOSAGE CALCULATIONS; ETHNIC GROUPS; FEMALE; GENETIC ASSOCIATION STUDIES; GENETIC LOCI; GENETICS, POPULATION; GENOTYPE; HUMANS; LINEAR MODELS; LINKAGE DISEQUILIBRIUM; MALE; MIDDLE AGED; MIXED FUNCTION OXYGENASES; OMAN; PHARMACOGENETICS; POLYMORPHISM, GENETIC; PROSPECTIVE STUDIES; VENOUS THROMBOSIS; WARFARIN;

EID: 84867923548     PISSN: 14345161     EISSN: 1435232X     Source Type: Journal    
DOI: 10.1038/jhg.2012.94     Document Type: Article

References (24)

1. Limdi, N. A., Wadelius, M., Cavallari, L., Eriksson, N., Crawford, D. C., Lee, M. T. et al.; on behalf of the IWPC. Warfarin pharmacogenetics: VKORC1 genotype as predictive as haplotype across three racial groups. Blood 115, 3827-3834 (2010
2. Klein, T. E., Altman, R. B., Eriksson, N., Gage, B. F., Kimmel, S. E., Lee, M. T. et al.; on behalf of the IWPC. Estimation of warfarin dose using linical and pharmacogenetic data. N. Engl. J. Med. 360, 753-764 (2009
3. Sagreiya, H., Berube, C., Wen, A., Ramakrishnan, R., Mir, A., Hamilton, A. et al. Extending and evaluating a warfarin dosing algorithm that includes CYP4F2 and pooled rare variants of CYP2C9. Pharmacogenet. Genomics 20, 407-413 (2010
4. Perini, J. A., Struchiner, C. J., Silva-Assunçao, E., Santana, I. S. C., Rangel, F., Ojopi, E. B. et al. Pharmacogenetics of warfarin: Development of a dosing algorithm for Brazilian patients. Clin. Pharmacol. Ther. 84, 722-728 (2008
5. Suarez-Kurtz, G Population diversity and the performance of warfarin dosing algorithms. Br. J. Clin. Pharmacol. 72, 451-453 (2011
6. Ansell, J., Hirsh, J., Hylek, E., Jacobson, A., Crowther, M. & Palareti, G. Pharmacology and management of the vitamin K Antagonists: American College of Chest Physicians evidence-based clinical practice guidelines (8th Edition). Chest 133, 160S-198S (2008
7. Geisen, C., Watzka, M., Sittinger, K., Steffens, M., Daugela, L., Seifried, E. et al. VKORC1 haplotypes and their impact on the inter-individual and inter-ethnical variability of oral anticoagulation. Thromb. Haemost. 94, 773-779 (2005
8. Spreafico, M., Lodigiani, C., Leeuwen, Y., Pizzotti, D., Rota, L. L., Rosendaal, F. R. et al. Effects of CYP2C9 and VKORC1 on INR variations and does requirements during initial phase of anticoagulation therapy. Pharmacogenomics 9, 1237-1250 (2008
9. Cavallari, L. H., Langaee, T. Y., Momary, K. M., Shapiro, N. L., Nutescu, E. A., Coty, W. A. et al. Genetic and clinical predictors of warfarin dose requirements in African Americans. Clin. Pharmacol. Therapeut. 87, 459-464 (2010
10. Gage, B. F., Eby, C., Johnson, J. A., Deych, E., Rieder, M. J., Ridker, P. M. et al. Use of Pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin. Clin. Pharmacol. Therapeut. 84, 326-331 (2008
11. Perini, J. A., Struchiner, C. J., Silva-Assuncao, E., Santana, I. S. C., Rangel, F., Ojopi, E. B. et al. Pharmacogenetics of warfaarin: Development of a dosing algorithm for Brazilian patients. Clin. Pharmacol. Therapeut 84, 722-728 (2008
12. Zhu, Y., Shennan, M., Reynolds, K. K., Johnson, N. A., Herrnberger, M. R., Valdes, Jr R. et al. Estimation of warfarin maintainance dose based on VKORC1 (-1639G4A) and CYP2C9 genotypes. Clin. Chem. 53, 1199-1205 (2007
13. Wadelius, M., Chen, L. Y., Lindh, J. D., Eriksson, N., Ghori, M. J., Bumpstead, S. et al. The largest prospective warfarin-treated cohort supports genetic forcasting. Blood 113, 784-792 (2009
14. Rieder, M., Reiner, A., Gage, B., Nickerson, D., Eby, C., McLeod, H. L. et al. Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N. Engl. J. Med. 352, 2285-2293 (2005
15. Limdi, N. A., Arnett, D. K., Goldstein, J. A., Beasley, T. M., McGwin, G., Adler, B. K. et al. Influence of CYP2C9 and VKORC1 on warfarin dose, anticoagulation attainment and maintenance among European-Americans and African-Americans. Pharmacogenomics 9, 511-526 (2008
16. Schelleman, H., Chen, J., Chen, Z., Christie, J., Newcomb, C. W. & Brensinger, C. M. Dosing algorithms to predict warfarin maintainance dose in Caucasians and African Americans. Clin. Pharmacol. Theraput. 84, 332-339 (2008
17. Lee, S. C., Ng, S. S., Oldenburg, J., Chong, P. Y., Rost, S., Guo, J. Y. et al. Interethnic variability of warfarin maintenance requirement is explained by VKORC1 genotype in Asian population. Clin. Pharmacol. Theraput. 79, 197-205 (2006
18. Perini, J. A., Struchiner, C. J., Silva-Assuncao, E. & Suarez-Kurtz, G. Impact of CYP4F2 rs 108622 on the stable warfarin dose in an admixed patient cohort. Clin. Pharmacol. Theraput. 87, 417-420 (2010
19. McDonald, M. G., Reider, M. J., Nakano, M., Hsia, C. K. & Rettie, A. E. CYP4F2 is a vitamin K1 oxidase: An explanation for altered warfarin dose in carrier of the V433M variant. Mol. Phamarcol. 75, 1337-1346 (2009
20. Caulifield, T., Fullerton, S. M., Ali-Khan, S. E., Arbour, L., Buchard, E. G., Cooper, R. S. et al. Race and ancestry in biomedical research: Exploring the challenges. Genome Med. 1, 8 (2009
21. Pathare, A. V., Zadjali, S. A., Misquith, R., Alkindi, S. S., Panjwani, V., Lapoumeroulie, C. et al. Warfarin pharmacogenetics: Polymorphisms of the CYP2C9, CYP4F2, and VKORC1 loci in a genetically admixed Omani population. Hum. Biol. 84, 67-77 (2012
22. Voora, D., Koboldt, D. C., King, C. R., Lenzini, P. A., Eby, C. S. et al. A polymorphism in the VKORC1 regulator calumenin predicts higher warfarin dose requirements in African Americans. Clin. Pharmacol. Theraput 87, 445-451 (2010
23. Takeuchi, F., McGinnis, R., Bourgeois, S., Barnes, C., Eriksson, N., Soranzo, N. et al. A genome-wide association study confirms VKORC1, CYP2C9, and CYP4F2 as principal genetic determinants of warfarin dose. PLoS Genet. 5, 1-9 (2009
24. Cooper, G. M., Johnson, J. A., Langaee, T. Y., Feng, H., Stanaway, I. B., Schwarz, U. I. et al. A genome-wide scan for common genetic variants with a large influence on warfarin maintenance dose. Blood 112, 1022-1027 (2008)